Current stock page

Stock Analysis

Immunovant, Inc. (IMVT) Stock Analysis

Immunovant, Inc. (IMVT) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

IMVT Stock Analysis Summary

Immunovant, Inc. (IMVT) currently has an AIQ Score of 52/100, indicating a neutral setup. Momentum is the strongest factor at 61/100. Quality is the weakest current factor at 42/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

IMVT at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$34.18
AIQ Score52/100
Overall ViewNeutral
Technical Analysis ConsensusStrong Buy
Market Cap$7.06B
P/E Ratio (TTM)-13.35
Forward P/E—
EPS (Q2 FY2027)-$0.47
Revenue (Q2 FY2027)$0
Dividend Yield (TTM)0.00%
Beta1.58
Volume864.88K
52-week range$21.86-$45.42
RSI 1458.06
50-Day SMA$32.64
200-Day SMA$32.35
Analyst Price Target—
Next EarningsFeb 5, 2027
As of Nov 13, 2026 · Market close

IMVTImmunovant, Inc.

Healthcare / Biotechnology

Relative Leader / Watch

Strong Relative Position

NeutralEdge 9/10
$34.18−$0.87 (−2.48%)

Latest quote

  • Momentum
    61
  • Value
    —
  • Quality
    42
  • Risk resilience
    52
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

IMVT Stock Analysis Summary

Immunovant, Inc. (IMVT) currently has an AIQ Score of 52/100, indicating a neutral setup. Momentum is the strongest factor at 61/100. Quality is the weakest current factor at 42/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Neutral

In a neutral regime, IMVT has AIQ Score of 52/100 with Momentum base of 61/100 and fading Quality at 42/100. Wait for component alignment before adding exposure.

Healthcare · -2.48% stock move · IMVT classified in Biotechnology.

Current Evidence

NeutralIMVT is in a neutral AIQ regime; Momentum is the strongest visible factor at 61/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is IMVT Bullish or Bearish Right Now?

IMVT currently has a neutral overall setup. Momentum is the strongest factor at 61/100, while Quality is weakest at 42/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.

Bull Case
  • - Price is +4.73% above its 50-day SMA.
  • - Technical consensus has more buy votes than sell votes (33 vs 6).
Bear Case
  • - No strong bearish evidence is available in the current snapshot.

Current Consensus

IMVT's Technical Analysis Consensus is currently Strong Buy, with 33 buy, 7 neutral, and 6 sell votes. IMVT's 14-day RSI is 58.06, which places the stock in a constructive momentum range. IMVT's beta is 1.58, indicating greater market sensitivity than the broad market.

Signal Confidence
High agreement

What Changed in IMVT?

The largest recent change in IMVT is Momentum moving up by 5.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.

AIQ Score
+3.0
Momentum
+5.0
Quality
+2.0
Risk
-2.0

What Would Change the IMVT Outlook?

The current neutral outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

IMVT Decision Framework

Public evidence layers, setup checks, and risk context for Immunovant, Inc..

Immunovant, Inc. (IMVT) Stock Analysis

Immunovant, Inc. has an AIQ Score of 52/100 in a Neutral regime. Momentum is strongest at 61/100. Beta is 1.58, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextIMVT is in a Neutral AIQ regime with score 52/100.
Signal ConflictThe primary conflict is that momentum leads at 61/100 while quality lags at 42/100.
Factor EvidenceMomentum 61/100 · Quality 42/100 · Risk 52/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthWait

Momentum is the strongest factor at 61/100.

TimingWait

Momentum is 61/100 and RSI (14) is 58.1.

Regime fitWait

IMVT is in a Neutral regime at 52/100.

Risk controlWait

Risk factor is 52/100 with beta 1.58 and annual volatility 58.62%.

ConflictPass

Current conflict: momentum leads at 61/100 while quality lags at 42/100.

AIQ Score
52/100
Price
$34.18
Beta
1.58
RSI (14)
58.1

IMVT Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

IMVT Fundamentals

IMVT valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$0
Net income
-$97.25M
Free cash flow
-$83.22M
View full IMVT fundamental analysis

IMVT Technical Analysis

IMVT technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Buy
RSI 14
58.06
Price vs SMA-50
+4.73%
View full IMVT technical analysis

IMVT Stock Catalysts

Track IMVT earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Feb 5, 2027
Analyst target
—
News items
4
View IMVT earnings and stock catalysts

IMVT Dividend Analysis

IMVT dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View IMVT dividend history and analysis

IMVT Financial Data

IMVT revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$0
EPS
-$0.47
Periods
8
View IMVT financials

IMVT Risk Analysis

IMVT volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
1.58
Risk score
52/100
1Y volatility
58.62%
View IMVT risk analysis

IMVT Stock News

IMVT stock news, market tone, recent headlines, and catalyst context.

News items
4
Updated
Nov 15, 2026
Sentiment
—
Read IMVT stock news

IMVT vs Biotechnology Peers

Current peer cohort: IMVT · INBX · INSM · INVA · IRON. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
IMVT
Current stock
52/100—61/10052/1000.958.62%Current
INBX
Inhibrx Biosciences Inc.
40/100—50/10040/1000.4982.28%IMVT vs INBX
INSM
Insmed Incorporated
57/10055/10061/10049/100-0.4863.12%IMVT vs INSM
INVA
Innoviva, Inc.
67/10092/10043/10074/100-0.6425.21%IMVT vs INVA
IRON
Disc Medicine, Inc.
65/100—75/10051/1000.163.55%IMVT vs IRON
Pairwise Compare links: INBX · INSM · INVA · IRONIMVT vs INBXIMVT vs INSMIMVT vs INVAIMVT vs IRONCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a IMVT stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for IMVT: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
-13.35
As of Nov 13, 2026
Revenue growth
—
Gross margin
100.00%
Current debt / equity
0
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$0
Quarter net income
-$97.25M
Quarter free cash flow
-$83.22M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Bullish
Momentum
Bullish
RSI 14
58.06
MACD
0.84

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
52/100
Beta
1.58
Annual volatility
58.62%
Max drawdown
-40.55%

IMVT Stock FAQ

What is IMVT stock price today?

Immunovant, Inc.'s current stock price is $34.18. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is IMVT bullish or bearish right now?

IMVT's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is IMVT's market cap?

IMVT's market cap is $7.06B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is IMVT's current P/E ratio?

IMVT's current P/E ratio is -13.35 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is IMVT's RSI?

IMVT's 14-day RSI is 58.06 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is IMVT above its 50-day and 200-day moving averages?

IMVT is 4.73% from its 50-day SMA and 5.67% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is IMVT's next earnings date?

IMVT's next earnings date is currently listed as Feb 5, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does IMVT pay a dividend?

IMVT's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.